175 related articles for article (PubMed ID: 8699237)
1. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.
Fulton D; Urtasun R; Forsyth P
J Neurooncol; 1996 Feb; 27(2):149-55. PubMed ID: 8699237
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of fotemustine in recurrent supratentorial malignant gliomas.
Frenay M; Giroux B; Khoury S; Derlon JM; Namer M
Eur J Cancer; 1991; 27(7):852-6. PubMed ID: 1834116
[TBL] [Abstract][Full Text] [Related]
4. Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study.
Sanson M; Ameri A; Monjour A; Sahmoud T; Ronchin P; Poisson M; Delattre JY
Eur J Cancer; 1996 Dec; 32A(13):2229-35. PubMed ID: 9038603
[TBL] [Abstract][Full Text] [Related]
5. Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study.
Ashby LS; Shapiro WR
J Neurooncol; 2001 Jan; 51(1):67-86. PubMed ID: 11349883
[TBL] [Abstract][Full Text] [Related]
6. Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study.
Ameri A; Poisson M; Chauveinc L; Chen QM; Delattre JY
J Neurooncol; 1997 Apr; 32(2):155-60. PubMed ID: 9120545
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
[TBL] [Abstract][Full Text] [Related]
8. Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study.
Ameri A; Poisson M; Chen QM; Delattre JY
J Neurooncol; 1993 Jul; 17(1):43-6. PubMed ID: 8120571
[TBL] [Abstract][Full Text] [Related]
9. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery.
Rostomily RC; Spence AM; Duong D; McCormick K; Bland M; Berger MS
Neurosurgery; 1994 Sep; 35(3):378-88; discussion 388. PubMed ID: 7800129
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Korones DN; Smith A; Foreman N; Bouffet E
Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Jaeckle KA; Hess KR; Yung WK; Greenberg H; Fine H; Schiff D; Pollack IF; Kuhn J; Fink K; Mehta M; Cloughesy T; Nicholas MK; Chang S; Prados M;
J Clin Oncol; 2003 Jun; 21(12):2305-11. PubMed ID: 12805331
[TBL] [Abstract][Full Text] [Related]
12. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide.
Chamberlain MC
Arch Neurol; 1997 May; 54(5):554-8. PubMed ID: 9152112
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Prados MD; Lamborn K; Yung WK; Jaeckle K; Robins HI; Mehta M; Fine HA; Wen PY; Cloughesy T; Chang S; Nicholas MK; Schiff D; Greenberg H; Junck L; Fink K; Hess K; Kuhn J;
Neuro Oncol; 2006 Apr; 8(2):189-93. PubMed ID: 16533878
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
15. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen.
Couldwell WT; Hinton DR; Surnock AA; DeGiorgio CM; Weiner LP; Apuzzo ML; Masri L; Law RE; Weiss MH
Clin Cancer Res; 1996 Apr; 2(4):619-22. PubMed ID: 9816211
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
17. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha.
Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Ikeda K; Soma G; Fukushima T
Anticancer Res; 2002; 22(4):2447-53. PubMed ID: 12174942
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
Afra D; Sipos L; Vitanovics D
Ideggyogy Sz; 2002 Jan; 55(1-2):38-44. PubMed ID: 12122942
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
20. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
